Correction to: Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-020-0398-2, published online 13 May 2020
Western blot images of Atg12 in Fig. 2a and GAPDH in Fig. 4d was inadvertently misplaced in the process of assembling figures. The correct version is shown. The corrigendum does not affect the interpretation of data and conclusions. The authors apologize for any inconvenience this may have caused.
Fig. 2 DCZ5248 inhibits autophagy flux. a HT-29 cells were treated with DCZ5248 for 12 h, and whole-cell lysates were analyzed by Western blotting.
Fig. 4 The inhibition of autophagy by DCZ5248 is independent of Hsp90. d HT-29 cells transfected with Hsp90-target siRNA or control Hsp90 siRNA were treated with 0.3 μM DCZ5248.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, Xl., Liu, P., Zhu, Wl. et al. Author Correction: DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer. Acta Pharmacol Sin 45, 660 (2024). https://doi.org/10.1038/s41401-023-01184-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-023-01184-6
